Saturday 17 October 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.1%, free cash flow fell 65.0% and total debt fell 88.4%, each against the same quarter a year earlier.
4.75
0.15
−3.06%
Follow PYPD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.57 | 1.97 | 1.78 | 1.35 |
Net Debt/EBITDA |
2.22 | 1.42 | 1.33 | 0.86 | |
Debt/Assets |
9.00% | 4.43% | 4.18% | 0.00% | |
Debt/Equity |
0.16 | 0.09 | 0.09 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 3.29 | 0.00 | 1.76 | |
Capex/Depreciation |
— | (0.14) | — | (0.27) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | (1.72) | 0.00 | (0.62) | |
Cash per Share |
0.95 | 0.80 | 0.51 | 0.30 | |
Shareholders Equity per Share |
0.77 | 0.67 | 0.40 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.77 | 0.67 | 0.40 | 0.24 | |
Free Cash Flow |
— | (28.09) | — | (14.04) | |
Working Capital |
11.96 | 7.49 | 5.51 | 2.28 | |
Capital Expenditures |
— | (0.21) | — | (0.21) | |
Net Current Asset Value |
8.11 | 3.89 | 2.18 | (0.96) | |
| Other line items | |||||
Quick Ratio |
2.49 | 1.70 | 1.58 | 1.03 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (1.70) | 0.00 | (0.61) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Average Payables |
1.77 | 2.63 | 1.78 | 2.12 | |
Average Assets |
23.22 | 23.76 | 18.00 | 26.46 | |
Average Common Equity |
8.76 | 9.33 | 4.43 | 12.93 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates